Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06016972
Other study ID # QC-111-201
Secondary ID Osprey
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 15, 2024
Est. completion date September 5, 2024

Study information

Verified date August 2023
Source Qlaris Bio, Inc.
Contact Lisa Brandano
Phone 9789302103
Email lbrandano@qlaris.bio
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.


Description:

A randomized, active- and vehicle-controlled, multi-site, double-masked study to evaluate the safety and tolerability of QLS-111 versus vehicle in subjects with primary open-angle glaucoma or ocular hypertension. Primary objective is to evaluate the ocular and systemic safety and tolerability of 3 concentrations of QLS-111 compared to vehicle control. Secondary objective is to evaluate the ocular hypotensive efficacy of 3 concentrations of QLS-111 with once daily morning (QAM), once daily evening (QPM), and twice daily (BID) dosing versus vehicle with QAM, QPM, and BID dosing.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date September 5, 2024
Est. primary completion date September 5, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years or older - Able to provide written acknowledgement of giving informed consent - Best corrected visual acuity (BCVA) 20/200 or better Bilateral POAG or OHT with documented historic IOP value(s) =24 mmHg, in either eye - Post-washout IOP =22 mmHg in morning on Visits 2 and 3 and =18 mmHg at noon on Visit 2 Exclusion Criteria: - IOP >34 mmHg - Severe glaucomatous damage that would preclude safe washout of prescribed ocular hypotensive medications - Previous glaucoma surgery, certain procedures (trabeculotomy, shunt/tubes, cyclodestructive procedure) (selective laser trabeculoplasty (SLT) allowed if done no earlier than 1 year from study, some minimally invasive glaucoma surgeries are allowed if done no earlier than 1 year from study) - Ocular trauma, ocular infections, ocular inflammation, herpes simplex keratitis of eye - Use of other ophthalmic concomitant medications during the study - Uncontrolled hypertension or hypotension - Significant systemic or psychiatric disease - Participation in other investigational trial 30 days prior to screening or previous enrollment and treatment with Qlaris investigational product - Pregnant or lactating

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Experimental: QLS-111 ophthalmic solution, (0.015%)
QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Experimental: QLS-111 ophthalmic solution, (0.03%)
QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Experimental: QLS-111 ophthalmic solution, (0.075%)
QLS-111 ophthalmic solution, (0.075%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Other:
QLS-111 ophthalmic vehicle solution
Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

Locations

Country Name City State
United States Coastal Research Associates, LLC Roswell Georgia

Sponsors (1)

Lead Sponsor Collaborator
Qlaris Bio, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of ocular symptoms and ocular treatment-emergent adverse events (TEAEs) Ocular safety and tolerability: adverse events (AEs) 21 days
Primary Clinically significant change in visual acuity Ocular safety and tolerability: visual acuity 21 days
Primary Clinically significant change in findings on slit lamp exam Ocular safety and tolerability: slit lamp 21 days
Primary Clinically significant change in findings on fundus exam Ocular safety and tolerability: fundus 21 days
Primary Incidence of systemic TEAEs Systemic safety and tolerability: AEs 21 days
Primary Clinically significant changes in blood pressure (BP) Systemic safety and tolerability: vital signs 21 days
Primary Clinically significant changes in heart rate (HR) Systemic safety and tolerability: vital signs 21 days
Secondary Change from baseline (CFB) of diurnal intraocular pressure (IOP) in the study eye Ocular hypotensive efficacy: diurnal IOP CFB 21 days
Secondary CFB in IOP at various timepoints in the study eye Ocular hypotensive efficacy: CFB for multiple timepoints throughout day up to 21 days
See also
  Status Clinical Trial Phase
Completed NCT01085357 - Study of an Implantable Device for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery N/A
Completed NCT02434692 - Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG) N/A
Completed NCT02700984 - A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial N/A
Completed NCT01517477 - One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects N/A
Terminated NCT01180062 - Safety Study of Latanoprost Slow Release Insert Phase 1
Terminated NCT03478293 - iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications N/A
Completed NCT01166659 - Study of CyPass Implantation In Patients With Open Angle Glaucoma Refractory to Single or Multi-agent Topical Therapy N/A
Completed NCT01252849 - Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects N/A
Active, not recruiting NCT00902109 - Study to Compare Standard Perimetry With the New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) in Glaucoma Patients N/A

External Links